Satdarshan P Monga

List of Publications by Year
in descending order

210 papers	10,910 citations	28190 55 h-index	35952 97 g-index
219 all docs	219 docs citations	219 times ranked	11968 citing authors

#	Article	IF	Citations
1	Wnt/Î²-Catenin Signaling Promotes Renal Interstitial Fibrosis. Journal of the American Society of Nephrology: JASN, 2009, 20, 765-776.	3.0	510
2	Î²-Catenin Activation Promotes Immune Escape and Resistance to Antiâ€“PD-1 Therapy in Hepatocellular Carcinoma. Cancer Discovery, 2019, 9, 1124-1141.	7.7	498
3	WNT/Î²-catenin signaling in liver health and disease. Hepatology, 2007, 45, 1298-1305.	3.6	449
4	Î²-Catenin Signaling and Roles in Liver Homeostasis, Injury, and Tumorigenesis. Gastroenterology, 2015, 148, 1294-1310.	0.6	369
5	Wnt/Î²-Catenin Signaling Promotes Podocyte Dysfunction and Albuminuria. Journal of the American Society of Nephrology: JASN, 2009, 20, 1997-2008.	3.0	356
6	Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas. Hepatology, 2006, 44, 1012-1024.	3.6	319
7	Wnt/Î²-Catenin Signaling in Liver Development, Homeostasis, and Pathobiology. Annual Review of Pathology: Mechanisms of Disease, 2018, 13, 351-378.	9.6	288
8	Changes in WNT/Î²-catenin pathway during regulated growth in rat liver regeneration. Hepatology, 2001, 33, 1098-1109.	3.6	257
9	Beta-catenin signaling, liver regeneration and hepatocellular cancer: Sorting the good from the bad. Seminars in Cancer Biology, 2011, 21, 44-58.	4.3	220
10	Î²-catenin antisense studies in embryonic liver cultures: Role in proliferation, apoptosis, and lineage specification. Gastroenterology, 2003, 124, 202-216.	0.6	216
11	Beta-catenin signaling in murine liver zonation and regeneration: A Wnt-Wnt situation!. Hepatology, 2014, 60, 964-976.	3.6	205
12	High-mobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases. Hepatology, 2012, 55, 1863-1875.	3.6	200
13	Aberrant Wnt/Î²-Catenin Signaling in Pancreatic Adenocarcinoma. Neoplasia, 2006, 8, 279-289.	2.3	184
14	Î²-Catenin deletion in hepatoblasts disrupts hepatic morphogenesis and survival during mouse development. Hepatology, 2008, 47, 1667-1679.	3.6	170
15	Expression of Notch-1 and its ligand Jagged-1 in rat liver during liver regeneration. Hepatology, 2004, 39, 1056-1065.	3.6	163
16	Wnt/Î²-catenin signaling mediates oval cell response in rodents. Hepatology, 2008, 47, 288-295.	3.6	157
17	Enhanced liver regeneration following changes induced by hepatocyte-specific genetic ablation of integrin-linked kinase. Hepatology, 2009, 50, 844-851.	3.6	147
18	Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene. Hepatology, 2009, 49, 821-831.	3.6	144

#	Article	IF	Citations
19	Beta-Catenin Activation Promotes Liver Regeneration after Acetaminophen-Induced Injury. American Journal of Pathology, 2009, 175, 1056-1065.	1.9	143
20	Pro-Regenerative Signaling after Acetaminophen-Induced Acute Liver Injury in Mice Identified Using a Novel Incremental Dose Model. American Journal of Pathology, 2014, 184, 3013-3025.	1.9	143
21	Role of Wnt/Î²-catenin signaling in liver metabolism and cancer. International Journal of Biochemistry and Cell Biology, 2011, 43, 1021-1029.	1.2	138
22	Accelerated liver regeneration and hepatocarcinogenesis in mice overexpressing serine-45 mutant Î²-catenin. Hepatology, 2010, 51, 1603-1613.	3.6	133
23	Smad Proteins and Hepatocyte Growth Factor Control Parallel Regulatory Pathways That Converge on Î²1-Integrin To Promote Normal Liver Development. Molecular and Cellular Biology, 2001, 21, 5122-5131.	1.1	131
24	Wnt'er in liver: Expression of Wnt and frizzled genes in mouse. Hepatology, 2007, 45, 195-204.	3.6	131
25	Wnt impacts growth and differentiation in ex vivo liver development. Experimental Cell Research, 2004, 292, 157-169.	1.2	130
26	Defective HNF4alpha-dependent gene expression as a driver of hepatocellular failure in alcoholic hepatitis. Nature Communications, 2019, 10, 3126.	5.8	124
27	The processing and utilization of hepatocyte growth factor/scatter factor following partial hepatectomy in the rat. Hepatology, 2001, 34, 688-693.	3.6	122
28	Liver-Specific Î²-Catenin Knockout Mice Exhibit Defective Bile Acid and Cholesterol Homeostasis and Increased Susceptibility to Diet-Induced Steatohepatitis. American Journal of Pathology, 2010, 176, 744-753.	1.9	108
29	Activation of Wnt/Î²-catenin pathway during hepatocyte growth factorâ€“induced hepatomegaly in mice. Hepatology, 2006, 44, 992-1002.	3.6	107
30	siRNA-Mediated Î²-Catenin Knockdown in Human Hepatoma Cells Results in Decreased Growth and Survival. Neoplasia, 2007, 9, 951-959.	2.3	107
31	Hepatocyteâ€Specific Î²â€Catenin Deletion During Severe Liver Injury Provokes Cholangiocytes to Differentiate Into Hepatocytes. Hepatology, 2019, 69, 742-759.	3.6	102
32	Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma. Cancer Research, 2019, 79, 4326-4330.	0.4	99
33	Liver Progenitors and Adult Cell Plasticity in Hepatic Injury and Repair: Knowns and Unknowns. Annual Review of Pathology: Mechanisms of Disease, 2020, 15, 23-50.	9.6	99
34	Endothelial Wnts regulate Î²â€catenin signaling in murine liver zonation and regeneration: A sequel to the Wntâ€“Wnt situation. Hepatology Communications, 2018, 2, 845-860.	2.0	98
35	Platelet-derived growth factor receptor-Î±: a novel therapeutic target in human hepatocellular cancer. Molecular Cancer Therapeutics, 2007, 6, 1932-1941.	1.9	96
36	Wnt/Î²-catenin signaling in hepatic organogenesis. Organogenesis, 2008, 4, 92-99.	0.4	93

#	Article	IF	Citations
37	Modeling a human hepatocellular carcinoma subset in mice through coexpression of met and pointâ€mutant Î²â€catenin. Hepatology, 2016, 64, 1587-1605.	3.6	92
38	Inhibiting Glutamine-Dependent mTORC1 Activation Ameliorates Liver Cancers Driven by Î²-Catenin Mutations. Cell Metabolism, 2019, 29, 1135-1150.e6.	7.2	92
39	Tyrosine residues 654 and 670 in Î²-catenin are crucial in regulation of Metâ€"Î²-catenin interactions. Experimental Cell Research, 2006, 312, 3620-3630.	1.2	83
40	Conditional Î²-catenin loss in mice promotes chemical hepatocarcinogenesis: Role of oxidative stress and platelet-derived growth factor receptor Î±/phosphoinositide 3-kinase signaling. Hepatology, 2010, 52, 954-965.	3.6	82
41	Novel Advances in Understanding of Molecular Pathogenesis of Hepatoblastoma: A Wnt/Î²-Catenin Perspective. Gene Expression, 2017, 17, 141-154.	0.5	82
42	Wnt signaling regulates hepatobiliary repair following cholestatic liver injury in mice. Hepatology, 2016, 64, 1652-1666.	3.6	76
43	Morpholino oligonucleotide-triggered Î²-catenin knockdown compromises normal liver regeneration. Journal of Hepatology, 2005, 43, 132-141.	1.8	72
44	Betaâ€catenin signaling in hepatic development and progenitors: Which way does the WNT blow?. Developmental Dynamics, 2011, 240, 486-500.	0.8	71
45	Î²-Catenin signaling in hepatocellular cancer: Implications in inflammation, fibrosis, and proliferation. Cancer Letters, 2014, 343, 90-97.	3.2	71
46	Elf3 encodes a novel 200-kD Î²-spectrin: role in liver development. Oncogene, 1999, 18, 353-364.	2.6	69
47	R-Etodolac decreases Î²-catenin levels along with survival and proliferation of hepatoma cells. Journal of Hepatology, 2007, 46, 849-857.	1.8	67
48	Targeting Î²â€catenin in hepatocellular cancers induced by coexpression of mutant Î²â€catenin and Kâ€Ras in mice. Hepatology, 2017, 65, 1581-1599.	3.6	67
49	Aryl Hydrocarbon Receptor Signaling Prevents Activation of Hepatic Stellate Cells and Liver Fibrogenesis in Mice. Gastroenterology, 2019, 157, 793-806.e14.	0.6	67
50	Pre-clinical and clinical investigations of metabolic zonation in liver diseases: The potential of microphysiology systems. Experimental Biology and Medicine, 2017, 242, 1605-1616.	1.1	66
51	Beta-catenin-NF-ÎºB interactions in murine hepatocytes: A complex to die for. Hepatology, 2013, 57, 763-774.	3.6	64
52	Fibroblast Growth Factor Enriches the Embryonic Liver Cultures for Hepatic Progenitors. American Journal of Pathology, 2004, 164, 2229-2240.	1.9	62
53	Tri-iodothyronine induces hepatocyte proliferation by protein kinase a-dependent Î²-catenin activation in rodents. Hepatology, 2014, 59, 2309-2320.	3.6	62
54	Update on the Mechanisms of Liver Regeneration. Seminars in Liver Disease, 2017, 37, 141-151.	1.8	62

#	Article	IF	Citations
55	Hdac1 Regulates Differentiation of Bipotent Liver Progenitor Cells During Regeneration via Sox9b and Cdk8. Gastroenterology, 2019, 156, 187-202.e14.	0.6	59
56	Intratumoral Therapy of Cisplatin/Epinephrine Injectable Gel for Palliation in Patients With Obstructive Esophageal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2000, 23, 386-392.	0.6	58
57	Functional compensation precedes recovery of tissue mass following acute liver injury. Nature Communications, 2020, 11, 5785.	5.8	56
58	Î²-Catenin and Met Deregulation in Childhood Hepatoblastomas. Pediatric and Developmental Pathology, 2005, 8, 435-447.	0.5	53
59	Mouse Fetal Liver Cells in Artificial Capillary Beds in Three-Dimensional Four-Compartment Bioreactors. American Journal of Pathology, 2005, 167, 1279-1292.	1.9	53
60	Dysregulated Bile Transporters and Impaired Tight Junctions During Chronic Liver Injury in Mice. Gastroenterology, 2018, 155, 1218-1232.e24.	0.6	53
61	Î²â€Catenin regulation of farnesoid X receptor signaling and bile acid metabolism during murine cholestasis. Hepatology, 2018, 67, 955-971.	3.6	49
62	Coordinated Activities of Multiple Myc-dependent and Myc-independent Biosynthetic Pathways in Hepatoblastoma. Journal of Biological Chemistry, 2016, 291, 26241-26251.	1.6	48
63	Î²-Catenin is essential for ethanol metabolism and protection against alcohol-mediated liver steatosis in mice. Hepatology, 2012, 55, 931-940.	3.6	47
64	Blocking integrin Î±4Î²7-mediated CD4 T cell recruitment to the intestine and liver protects mice from western diet-induced non-alcoholic steatohepatitis. Journal of Hepatology, 2020, 73, 1013-1022.	1.8	47
65	Praja1, a novel gene encoding a RING-H2 motif in mouse development. Oncogene, 1997, 15, 2361-2368.	2.6	44
66	MAN2A1â€"FER Fusion Gene Is Expressed by Human Liver and Other Tumor Types and Has Oncogenic Activity in Mice. Gastroenterology, 2017, 153, 1120-1132.e15.	0.6	44
67	Î³-Catenin at Adherens Junctions: Mechanism and Biologic Implications in Hepatocellular Cancer after Î²-Catenin Knockdown. Neoplasia, 2013, 15, 421-IN19.	2.3	43
68	Direct Pharmacological Inhibition of Î²-Catenin by RNA Interference in Tumors of Diverse Origin. Molecular Cancer Therapeutics, 2016, 15, 2143-2154.	1.9	43
69	Hepatocyte Î³-catenin compensates for conditionally deleted Î²-catenin at adherens junctions. Journal of Hepatology, 2011, 55, 1256-1262.	1.8	42
70	Thyroid Hormone Receptor Î² Agonist Induces Î²-Catenin-Dependent Hepatocyte Proliferation in Mice: Implications in Hepatic Regeneration. Gene Expression, 2016, 17, 19-34.	0.5	42
71	ADAR1 Prevents Liver Injury from Inflammation and Suppresses Interferon Production in Hepatocytes. American Journal of Pathology, 2015, 185, 3224-3237.	1.9	41
72	PanIN-Specific Regulation of Wnt Signaling by HIF2Î± during Early Pancreatic Tumorigenesis. Cancer Research, 2013, 73, 4781-4790.	0.4	40

#	Article	IF	Citations
73	Dual catenin loss in murine liver causes tight junctional deregulation and progressive intrahepatic cholestasis. Hepatology, 2018, 67, 2320-2337.	3.6	40
74	Abnormal lipid processing but normal long-term repopulation potential of <i>mycâˆ’/âˆ’</i> hepatocytes. Oncotarget, 2016, 7, 30379-30395.	0.8	39
75	Î²-Catenin Regulates Vitamin C Biosynthesis and Cell Survival in Murine Liver. Journal of Biological Chemistry, 2009, 284, 28115-28127.	1.6	38
76	Bromodomain and extraterminal (BET) proteins regulate biliary-driven liver regeneration. Journal of Hepatology, 2016, 64, 316-325.	1.8	38
77	β-Catenin Knockdown in Liver Tumor Cells by a Cell Permeable Gamma Guanidine-based Peptide Nucleic Acid. Current Cancer Drug Targets, 2013, 13, 867-878.	0.8	37
78	Platelet-Derived Growth Factor Receptor Î± Contributes to Human Hepatic Stellate Cell Proliferation and Migration. American Journal of Pathology, 2017, 187, 2273-2287.	1.9	37
79	Î²-Catenin and Yes-Associated Protein 1 Cooperate in Hepatoblastoma Pathogenesis. American Journal of Pathology, 2019, 189, 1091-1104.	1.9	37
80	Î²-Catenin regulation during matrigel-induced rat hepatocyte differentiation. Cell and Tissue Research, 2006, 323, 71-79.	1.5	36
81	Disparate Cellular Basis of Improved Liver Repair in Î²-Catenin-Overexpressing Mice After Long-Term Exposure to 3,5-Diethoxycarbonyl-1,4-Dihydrocollidine. American Journal of Pathology, 2010, 177, 1812-1822.	1.9	36
82	Muc1 is protective during kidney ischemia-reperfusion injury. American Journal of Physiology - Renal Physiology, 2015, 308, F1452-F1462.	1.3	35
83	Hepatic adenomas: Presumed innocent until proven to be beta-catenin mutated. Hepatology, 2006, 43, 401-404.	3.6	34
84	Complete response of Ctnnb1-mutated tumours to Î²-catenin suppression by locked nucleic acid antisense in a mouse hepatocarcinogenesis model. Journal of Hepatology, 2015, 62, 380-387.	1.8	34
85	Role of Î²-catenin in development of bile ducts. Differentiation, 2016, 91, 42-49.	1.0	34
86	Calpain Induces N-terminal Truncation of Î²-Catenin in Normal Murine Liver Development. Journal of Biological Chemistry, 2012, 287, 22789-22798.	1.6	33
87	Mice lacking liver-specific Î²-catenin develop steatohepatitis and fibrosis after iron overload. Journal of Hepatology, 2017, 67, 360-369.	1.8	33
88	Axis inhibition protein 1 (Axin1) Deletionâ€“Induced Hepatocarcinogenesis Requires Intact Î²â€Catenin but Not Notch Cascade in Mice. Hepatology, 2019, 70, 2003-2017.	3.6	33
89	Induction of Nuclear Translocation of Constitutive Androstane Receptor by Peroxisome Proliferator-activated Receptor Î± Synthetic Ligands in Mouse Liver. Journal of Biological Chemistry, 2007, 282, 36766-36776.	1.6	32
90	Identification and Characterization of a Novel Small-Molecule Inhibitor of Î²-Catenin Signaling. American Journal of Pathology, 2014, 184, 2111-2122.	1.9	32

#	Article	IF	Citations
91	Bloodâ€Bile Barrier: Morphology, Regulation, and Pathophysiology. Gene Expression, 2019, 19, 69-87.	0.5	32
92	Nuclear factor erythroid 2â€"related factor 2 and Î²â€Catenin Coactivation in Hepatocellular Cancer: Biological and Therapeutic Implications. Hepatology, 2021, 74, 741-759.	3.6	32
93	Activation of the Transcription Factor GLI1 by WNT Signaling Underlies the Role of SULFATASE 2 as a Regulator of Tissue Regeneration. Journal of Biological Chemistry, 2013, 288, 21389-21398.	1.6	31
94	Pegylated interferon alpha targets Wnt signaling by inducing nuclear export of Î²-catenin. Journal of Hepatology, 2011, 54, 506-512.	1.8	29
95	Spontaneous repopulation of Î²-catenin null livers with Î²-catenin-positive hepatocytes after chronic murine liver injury. Hepatology, 2011, 54, 1333-1343.	3.6	29
96	Valproic Acid Limits Pancreatic Recovery after Pancreatitis by Inhibiting Histone Deacetylases and Preventing Acinar Redifferentiation Programs. American Journal of Pathology, 2015, 185, 3304-3315.	1.9	29
97	WNT5A Inhibits Hepatocyte Proliferation and Concludes Î²-Catenin Signaling in Liver Regeneration. American Journal of Pathology, 2015, 185, 2194-2205.	1.9	29
98	Notch Inhibition Promotes Differentiation of Liver Progenitor Cells into Hepatocytes via <i>sox9b</i> Repression in Zebrafish. Stem Cells International, 2019, 2019, 1-11.	1.2	29
99	Loss of hepatocyte Î²-catenin protects mice from experimental porphyria-associated liver injury. Journal of Hepatology, 2019, 70, 108-117.	1.8	29
100	Role of Leukocyte Cell-Derived Chemotaxin 2 as a Biomarker in Hepatocellular Carcinoma. PLoS ONE, 2014, 9, e98817.	1.1	28
101	PDGFRÎ± in Liver Pathophysiology: Emerging Roles in Development, Regeneration, Fibrosis, and Cancer. Gene Expression, 2015, 16, 109-127.	0.5	28
102	Postponing the Hypoglycemic Response to Partial Hepatectomy Delays Mouse Liver Regeneration. American Journal of Pathology, 2016, 186, 587-599.	1.9	28
103	Lipid metabolic reprogramming in hepatic ischemiaâ€"reperfusion injury. Nature Medicine, 2018, 24, 6-7.	15.2	27
104	Î²-Catenin Loss in Hepatocytes Promotes Hepatocellular Cancer after Diethylnitrosamine and Phenobarbital Administration to Mice. PLoS ONE, 2012, 7, e39771.	1.1	27
105	Muc1 enhances the Î²-catenin protective pathway during ischemia-reperfusion injury. American Journal of Physiology - Renal Physiology, 2016, 310, F569-F579.	1.3	26
106	Role and Regulation of PDGFRÎ± Signaling in Liver Development and Regeneration. American Journal of Pathology, 2013, 182, 1648-1658.	1.9	25
107	TEA Domain Transcription Factor 4 Is the Major Mediator of Yes-Associated Protein Oncogenic Activity in Mouse and Human Hepatoblastoma. American Journal of Pathology, 2019, 189, 1077-1090.	1.9	25
108	Loss of Wnt Secretion by Macrophages Promotes Hepatobiliary Injury after Administration of 3,5-Diethoxycarbonyl-1, 4-Dihydrocollidine Diet. American Journal of Pathology, 2019, 189, 590-603.	1.9	24

#	Article	IF	Citations
109	NOTCH-YAP1/TEAD-DNMT1 Axis Drives Hepatocyte Reprogramming Into Intrahepatic Cholangiocarcinoma. Gastroenterology, 2022, 163, 449-465.	0.6	23
110	Inflammation and Ectopic Fat Deposition in the Aging Murine Liver Is Influenced by CCR2. American Journal of Pathology, 2020, 190, 372-387.	1.9	22
111	TBX3 functions as a tumor suppressor downstream of activated CTNNB1 mutants during hepatocarcinogenesis. Journal of Hepatology, 2021, 75, 120-131.	1.8	22
112	Impaired mitochondrial medium-chain fatty acid oxidation drives periportal macrovesicular steatosis in sirtuin-5 knockout mice. Scientific Reports, 2020, 10, 18367.	1.6	21
113	Cell cycleâ€“related kinase links androgen receptor and Î²-catenin signaling in hepatocellular carcinoma: Why are men at a loss?. Hepatology, 2012, 55, 970-974.	3.6	19
114	Thyroid Hormone Receptor-Î² Agonist GC-1 Inhibits Met-Î²-Cateninâ€“Driven Hepatocellular Cancer. American Journal of Pathology, 2017, 187, 2473-2485.	1.9	19
115	The Effect of Selective c-MET Inhibitor on Hepatocellular Carcinoma in the MET-Active, Î²-Catenin-Mutated Mouse Model. Gene Expression, 2018, 18, 135-147.	0.5	19
116	P-selectinâ€“deficient mice to study pathophysiology of sickle cell disease. Blood Advances, 2020, 4, 266-273.	2.5	19
117	Differential Mitogenic Effects of Single Chain Hepatocyte Growth Factor (HGF)/Scatter Factor and HGF/NK1 following Cleavage by Factor Xa. Journal of Biological Chemistry, 2002, 277, 14109-14115.	1.6	18
118	Diverse Basis of Î²-Catenin Activation in Human Hepatocellular Carcinoma: Implications in Biology and Prognosis. PLoS ONE, 2016, 11, e0152695.	1.1	18
119	Impaired Ribosomal Biogenesis by Noncanonical Degradation of <i>Î²</i>-Catenin during Hyperammonemia. Molecular and Cellular Biology, 2019, 39, .	1.1	18
120	Endoscopic treatment of gastric cancer with intratumoral cisplatin/epinephrine injectable gel: a case report. Gastrointestinal Endoscopy, 1998, 48, 415-417.	0.5	17
121	A general path for large-scale solubilization of cellular proteins: From membrane receptors to multiprotein complexes. Protein Expression and Purification, 2013, 87, 111-119.	0.6	17
122	Oncogenic potential of N-terminal deletion and S45Y mutant Î²-catenin in promoting hepatocellular carcinoma development in mice. BMC Cancer, 2018, 18, 1093.	1.1	17
123	Wnt/-Catenin Signaling and Liver Regeneration: Circuit, Biology, and Opportunities. Gene Expression, 2021, 20, 189-199.	0.5	17
124	Compensatory hepatic adaptation accompanies permanent absence of intrahepatic biliary network due to YAP1 loss in liver progenitors. Cell Reports, 2021, 36, 109310.	2.9	17
125	A Fbxo48 inhibitor prevents pAMPKÎ± degradation and ameliorates insulin resistance. Nature Chemical Biology, 2021, 17, 298-306.	3.9	16
126	Î²-Catenin Activation in Hepatocellular Cancer: Implications in Biology and Therapy. Cancers, 2021, 13, 1830.	1.7	16

#	Article	IF	Citations
127	Identification of a unique loss-of-function mutation in IGF1R and a crosstalk between IGF1R and Wnt/Î²-catenin signaling pathways. Biochimica Et Biophysica Acta - Molecular Cell Research, 2018, 1865, 920-931.	1.9	15
128	Terminal regions of Î²-catenin are critical for regulating its adhesion and transcription functions. Biochimica Et Biophysica Acta - Molecular Cell Research, 2016, 1863, 2345-2357.	1.9	14
129	Role and Regulation of p65/Î²-Catenin Association During Liver Injury and Regeneration: A â€œComplexâ€• Relationship. Gene Expression, 2017, 17, 219-235.	0.5	14
130	Role and Regulation of Wnt/Î²-Catenin in Hepatic Perivenous Zonation and Physiological Homeostasis. American Journal of Pathology, 2022, 192, 4-17.	1.9	14
131	Inhibition of p53 Sulfoconjugation Prevents Oxidative Hepatotoxicity and Acute Liver Failure. Gastroenterology, 2022, 162, 1226-1241.	0.6	14
132	High Frequency of Î²-Catenin Mutations in Mouse Hepatocellular Carcinomas Induced by a Nongenotoxic Constitutive Androstane Receptor Agonist. American Journal of Pathology, 2018, 188, 2497-2507.	1.9	13
133	No Zones Left Behind: Democratic Hepatocytes Contribute to Liver Homeostasis and Repair. Cell Stem Cell, 2020, 26, 2-3.	5.2	13
134	Yesâ€Associated Protein Is Crucial for Constitutive Androstane Receptorâ€Driven Hepatocyte Proliferation But Not for Induction of Drug Metabolism Genes in Mice. Hepatology, 2021, 73, 2005-2022.	3.6	13
135	Î²-Catenin Sustains and Is Required for YES-associated Protein Oncogenic Activity in Cholangiocarcinoma. Gastroenterology, 2022, 163, 481-494.	0.6	13
136	Mice with Hepatic Loss of the Desmosomal Protein Î³-Catenin Are Prone to Cholestatic Injury and Chemical Carcinogenesis. American Journal of Pathology, 2015, 185, 3274-3289.	1.9	12
137	Impaired Bile Secretion Promotes Hepatobiliary Injury in Sickle Cell Disease. Hepatology, 2020, 72, 2165-2181.	3.6	12
138	Elimination of Wnt Secretion From Stellate Cells Is Dispensable for Zonation and Development of Liver Fibrosis Following Hepatobiliary Injury. Gene Expression, 2019, 19, 121-136.	0.5	11
139	Dynamics and predicted drug response of a gene network linking dedifferentiation with beta-catenin dysfunction in hepatocellular carcinoma. Journal of Hepatology, 2019, 71, 323-332.	1.8	11
140	Bromodomain and Extraterminal (BET) Proteins Regulate Hepatocyte Proliferation in Hepatocyte-Driven Liver Regeneration. American Journal of Pathology, 2018, 188, 1389-1405.	1.9	10
141	Hepatocyte Wnts Are Dispensable During Diethylnitrosamine and Carbon Tetrachloride-Induced Injury and Hepatocellular Cancer. Gene Expression, 2018, 18, 209-219.	0.5	10
142	Hepatic Stellate Cellâ€“Specific Platelet-Derived Growth Factor Receptor-Î± Loss Reduces Fibrosis and Promotes Repair after Hepatocellular Injury. American Journal of Pathology, 2020, 190, 2080-2094.	1.9	10
143	Scaffolding Protein IQGAP1 Is Dispensable, but Its Overexpression Promotes Hepatocellular Carcinoma via YAP1 Signaling. Molecular and Cellular Biology, 2021, 41, .	1.1	10
144	Î²-Catenin-NF-ÎºB-CFTR interactions in cholangiocytes regulate inflammation and fibrosis during ductular reaction. ELife, 2021, 10, .	2.8	9

#	Article	IF	Citations
145	The Nitric Oxide DonorS-Nitrosoglutathione Reduces Apoptotic Primary Liver Cell Loss in a Three-Dimensional Perfusion Bioreactor Culture Model Developed for Liver Support. Tissue Engineering - Part A, 2010, 16, 861-866.	1.6	7
146	Hepatocyte-Derived Lipocalin 2 Is a Potential Serum Biomarker Reflecting Tumor Burden in Hepatoblastoma. American Journal of Pathology, 2018, 188, 1895-1909.	1.9	7
147	Role of YAP1 Signaling in Biliary Development, Repair, and Disease. Seminars in Liver Disease, 2022, 42, 017-033.	1.8	7
148	Genomic structure, chromosomal mapping, and muscle-specific expression of a PH domain-associated intronless gene, cded/lior. Mammalian Genome, 1999, 10, 62-67.	1.0	6
149	Hepatic Zonation Now on Hormones!. Hepatology, 2019, 69, 1339-1342.	3.6	6
150	Inside-Out or Outside-In: Choosing the Right Model of Hepatocellular Cancer. Gene Expression, 2020, 20, 139-145.	0.5	6
151	Hepatic Regenerative Medicine. American Journal of Pathology, 2014, 184, 306-308.	1.9	5
152	Chronic Activation of LXRÎ± Sensitizes Mice to Hepatocellular Carcinoma. Hepatology Communications, 2022, 6, 1123-1139.	2.0	5
153	Progressive Familial Intrahepatic Cholestasis: Is It Time to Transition to Genetic Cholestasis?. Journal of Pediatric Gastroenterology and Nutrition, 2021, 72, 641-643.	0.9	4
154	YAP1 activation and Hippo pathway signaling in the pathogenesis and treatment of intrahepatic cholangiocarcinoma. Advances in Cancer Research, 2022, , 283-317.	1.9	4
155	Updates on hepatic homeostasis and the many tiers of hepatobiliary repair. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 84-86.	8.2	3
156	BCL9/BCL9L in hepatocellular carcinoma: will it or Wnt it be the next therapeutic target?. Hepatology International, 2020, 14, 460-462.	1.9	3
157	Dual Î²-Catenin and Î³-Catenin Loss in Hepatocytes Impacts Their Polarity through Altered Transforming Growth Factor-Î² and Hepatocyte Nuclear Factor 4Î± Signaling. American Journal of Pathology, 2021, 191, 885-901.	1.9	3
158	A Quantitative Systems Pharmacology Platform Reveals NAFLD Pathophysiological States and Targeting Strategies. Metabolites, 2022, 12, 528.	1.3	3
159	Human fetal hepatocyte behavior in dynamic 3D perfusion culture bioreactors. Journal of Organ Dysfunction, 2007, 3, 183-192.	0.3	2
160	Wnt drives stem cell-mediated repair response after hepatic injury. Hepatology, 2013, 58, 1847-1850.	3.6	2
161	Depletion of hepatic forkhead box O1 does not affect cholelithiasis in male and female mice. Journal of Biological Chemistry, 2020, 295, 7003-7017.	1.6	2
162	Beta-catenin mutations in hepatocellular cancer, tumor cell metabolism, and the response of these tumors to mTOR inhibition.. Journal of Clinical Oncology, 2020, 38, 583-583.	0.8	2

#	Article	IF	Citations
163	Novel Genetic Activation Screening in Liver Repopulation and Cancer: Now CRISPR Than Ever!. Hepatology, 2018, 68, 408-411.	3.6	1
164	An epigenetic perspective on liver regeneration. Epigenomics, 2020, 12, 381-384.	1.0	1
165	A truncated betaâ€catenin species promotes hepatocyte differentiation in late fetal liver development. FASEB Journal, 2011, 25, 115.1.	0.2	1
166	NFE2L2 synergizes with betaâ€catenin gene mutations to induce HCC in patients and mice. FASEB Journal, 2019, 33, 126.12.	0.2	1
167	LiverClear: A versatile protocol for mouse liver tissue clearing. STAR Protocols, 2022, 3, 101178.	0.5	1
168	Editorial. Gene Expression, 2016, 17, 1-5.	0.5	0
169	Regulation of serâ€45 mutated betaâ€catenin in transgenic mouse livers. FASEB Journal, 2008, 22, 465.12.	0.2	0
170	Enhanced liver regeneration in transgenic mice overexpressing stable Î²â€catenin. FASEB Journal, 2008, 22, 465.10.	0.2	0
171	Regucalcin/SMPâ€30 is regulated by Î²â€catenin in the liver. FASEB Journal, 2008, 22, 1124.6.	0.2	0
172	Using Tyrosine 654 Phosphorylation of Betaâ€Catenin to Predict HCC Pathology. FASEB Journal, 2008, 22, 1124.7.	0.2	0
173	Betaâ€Catenin Expression in Pediatric Malignancies. FASEB Journal, 2008, 22, 1124.9.	0.2	0
174	Pegylatedâ€Interferon 2Î± (Pegâ€IFN) suppresses Î²â€catenin signaling in liver. FASEB Journal, 2008, 22, 321.4.	0.2	0
175	Loss of Betaâ€Catenin leads to compensatory changes in adherens and other junctions. FASEB Journal, 2010, 24, 348.1.	0.2	0
176	Nonâ€canonical Wnt Signaling in Embryonic Liver Development. FASEB Journal, 2010, 24, 749.1.	0.2	0
177	Î²â€Catenin and PDGFRÎ± signaling: Two Divergent mechanisms of hepatocellular carcinoma. FASEB Journal, 2010, 24, 349.4.	0.2	0
178	Activation of the Wnt/Î²â€catenin pathway leads to enhanced proliferation and liver regeneration in mice. FASEB Journal, 2010, 24, 236.1.	0.2	0
179	Repopulation of Î²â€catenin null liver with Î²â€catenin positive progenitor cells and tumor formation after longâ€term exposure to DDC. FASEB Journal, 2010, 24, 349.6.	0.2	0
180	A Truncated Betaâ€catenin Species Promotes Hepatocyte Differentiation in Late Embryonic Liver Development.. FASEB Journal, 2010, 24, 39.7.	0.2	0

#	Article	IF	Citations
181	PDGFRÎ± in Liver Development & Regeneration. FASEB Journal, 2011, 25, 115.4.	0.2	0
182	Role of HGF phosphorylation of betaâ€catenin at Y654 in embryonic mouse liver development. FASEB Journal, 2011, 25, 998.4.	0.2	0
183	Platelet Derived Growth factor Receptor Î± (PDGFRÎ±) in Liver Development. FASEB Journal, 2012, 26, 145.1.	0.2	0
184	Role of PDGFRÎ± in liver regeneration using hepatocytespecific knockout mice. FASEB Journal, 2012, 26, 274.9.	0.2	0
185	Cell proliferation in liver in response to iron overload is dependent on Î²â€catenin in male mice. FASEB Journal, 2012, 26, 145.3.	0.2	0
186	Antisense oligonucleotide therapy: combating aberrant Î²â€catenin in hepatocellular carcinoma using peptide nucleic acids without transfecting agents. FASEB Journal, 2012, 26, 397.5.	0.2	0
187	Wnt/Î²â€catenin pathway is activated by thyroid hormone and is required for its hepatomitogenic activity. FASEB Journal, 2012, 26, .	0.2	0
188	Development of novel small molecules targeting Î²â€catenin driven hepatocellular carcinoma. FASEB Journal, 2012, 26, 405.3.	0.2	0
189	Structural and functional implications of plakoglobin compensation due to Î²â€catenin loss in the liver. FASEB Journal, 2012, 26, 145.15.	0.2	0
190	Elucidating the role of Î²â€catenin in hepatocellular tumor angiogenesis. FASEB Journal, 2012, 26, 48.5.	0.2	0
191	Wnt5a inhibits Î²â€catenin signaling and proliferation in hepatocyte cultures: Implications in liver regeneration. FASEB Journal, 2013, 27, .	0.2	0
192	Absence of betaâ€catenin in liver attenuates bile duct injury. FASEB Journal, 2013, 27, 387.3.	0.2	0
193	Parenchymal Plateletâ€Derived Growth Factor Receptor Alpha Expression Is Dispensable For Hepatic Fibrosis During Chronic Liver Injury. FASEB Journal, 2015, 29, 53.7.	0.2	0
194	Activating Î²â€catenin Mutations And AKT Synergize To Promote Lipogenic Liver Tumors In Mice. FASEB Journal, 2015, 29, 611.8.	0.2	0
195	Mice Lacking Î²â€catenin In Liver Develop Hepatic Fibrosis In Response To Iron Overload. FASEB Journal, 2015, 29, 611.6.	0.2	0
196	Câ€Met And Î²â€catenin Coâ€delivery By Hydrodynamic Tail Vein Injection Promotes HCC Development In Mice. FASEB Journal, 2015, 29, 45.10.	0.2	0
197	Lymphocyte Specific Proteinâ€1 Suppresses Hepatocarcinogenesis Driven by Mutant Î²â€catenin and Met Overexpression. FASEB Journal, 2019, 33, 126.11.	0.2	0
198	mTOR Inhibition Delays Hepatoblastoma Growth in a Relevant Mouse Model. FASEB Journal, 2019, 33, 662.66.	0.2	0

#	Article	IF	Citations
199	Hepatocyteâ€Specific Î²â€catenin Deletion During Severe Liver Injury Provokes Cholangiocytes to Differentiate into Hepatocytes. FASEB Journal, 2019, 33, 369.2.	0.2	0
200	FGF19 and Met coâ€activation in murine liver induces HCC: Biological and clinical relevance. FASEB Journal, 2019, 33, 496.36.	0.2	0
201	Significant neutrophil accumulation, IL-18 deposition, and active inflammasome in tumor regions of human pancreatic ductal adenocarcinoma.. Journal of Clinical Oncology, 2019, 37, e15754-e15754.	0.8	0
202	Hepatocyte-derived intrahepatic cholangiocarcinoma requires Yap and Sox9: A clinical and preclinical analysis.. Journal of Clinical Oncology, 2020, 38, 582-582.	0.8	0
203	Functional Compensation Precedes Recovery of Tissue Mass Following Acute Liver Injury. FASEB Journal, 2020, 34, 1-1.	0.2	0
204	Concomitant NFE2L2 and CTNNB1 mutations in a subset of HCC patients: Synergy between Nrf2 and Wnt pathway in hepatocarcinogenesis. FASEB Journal, 2020, 34, 1-1.	0.2	0
205	Investigating the role of Fzdâ€7 in liver donation and regeneration. FASEB Journal, 2020, 34, 1-1.	0.2	0
206	Spatial transcriptomics reveals differences among genetic models of disruption in the Wntâ€betaâ€catenin signaling in hepatocytes. FASEB Journal, 2022, 36, .	0.2	0
207	Investigating Susceptibility of êžµâ€cateninâ€mutated Hepatocellular Carcinoma to Checkpoint Inhibitors. FASEB Journal, 2022, 36, .	0.2	0
208	Investigating the therapeutic efficacy of a novel mTORC1 inhibitor, RMCâ€6272, on liver tumors with bâ€catenin activation. FASEB Journal, 2022, 36, .	0.2	0
209	Understanding Molecular Heterogeneity in Hepatocellular Carcinoma. FASEB Journal, 2022, 36, .	0.2	0
210	In the Absence of YAP, TAZ Contributes to Hepatocyte Adaptation in Chronic Cholestasis in Females. FASEB Journal, 2022, 36, .	0.2	0